Cardiopulmonary bypass causes a systemic inflammatory reaction. Activation of leukocytes is an important part of this process, and is known to directly contribute to the development of postoperative coagulopathy, and thus hemorrhage. The removal of leukocytes from the cardiopulmonary bypass circulation, using specialized filters, has been proposed as one method for attenuating this inflammatory response. However, there is no consensus on its effectiveness. We used meta-analytical techniques to systematically assess the literature reporting on the potential effect of systemic leukofiltration on perioperative hemorrhage. Random effects modeling was used to calculate overall estimate, and heterogeneity was assessed. Systemic leukofiltration made no significant impact on chest tube drainage in the first 24 hours (weighted mean difference [WMD], ؊23.9 ml; 95% confidence interval [CI], ؊95.48 -47.61; p ‫؍‬ 0.51) or on the total packed red cell transfusion requirements of each patient (WMD, 7.84 ml; 95% CI, ؊80.13-95.81; p ‫؍‬ 0.86). The studies performed in this area thus far are highly heterogeneous, due in part to relatively poor-quality design and inadequate matching of their study groups. Although further high-quality trials on systemic leukofiltration may be appropriate, other strategies to reduce the coagulopathy associated with cardiopulmonary bypass should be sought and evaluated. ASAIO Journal 2007; 53:514 -521.
contributes to the development of postoperative complications, including respiratory failure, 6 and coagulopathy. 7 The link between CPB-stimulated leukocyte activation and the initiation of the coagulation cascade is complex, but similar in part to the acute-phase reaction seen in sepsis. 8 Leukocyte activation results in the marked release of proinflammatory mediators such as interleukin-1, tumor necrosis factor, and endotoxin, 9 all of which activate monocytes, leading to enhanced tissue factor surface expression, thrombin generation, and paradoxical activation and impairment of the coagulation system.
Several antiinflammatory strategies have been assessed to reduce CPB-related morbidity, including the perioperative administration of drugs, such as aprotinin, and technical alterations, such as temperature manipulation and heparin coating of the circuit. 10 These have met with mixed results. More recently, concurrent leukocyte removal with specialized filters has been proposed as a means of reducing the CPB-associated inflammatory response. Developed in the early 1990s from the technology already used to filter allogeneic blood transfusions, animal studies using blood transfusion filters suggested that if leukocytes were removed from the circulating blood during CPB, end-organ injury may be attenuated [11] [12] [13] and organ transplant survival rates increased. 14 Since then, leukodepleting filters have been tested at a variety of different sites within the CPB circuit, including the arterial line, 15 the venous line, 16 the blood cardioplegia line, 17 and for reinfused circuit blood, if collected during bypass. 18 Furthermore, in an attempt to improve the inconsistent results observed in these earlier studies, more intricate leukodepletion strategies have been developed. These include altering the timing of filtration, 19, 20 or the temperature at which it occurs, 21 and combining filtration techniques with each other 22 or with various pharmacologic interventions. 23 The effect of leukodepleting filters on CPB-associated coagulopathy is unclear. Some express concerns that leukofiltration leads to a reduction in platelet number, and hence results in an exacerbated coagulopathy. 18 However, others have suggested that a reduction in neutrophil-released inflammatory mediators leads to a reduced inflammatory response, limiting the coagulopathy and reducing blood loss. 24 There is no doubt that postoperative hemorrhage continues to be an important cause of morbidity and mortality in those undergoing CPB, 25 with blood product usage remaining in the range of 70 -80% in complex cardiac surgical cases, and the incidence of excessive postoperative bleeding approaching 11%. 26 Thus, any effect that leukofiltration may have on hemorrhage or blood transfusion requirements needs elucidating. The aim of this systematic review and meta-analysis is to determine the potential effect of systemic leukofiltration on hemorrhage and blood transfusion requirements in patients undergoing CPBassisted cardiac surgery.
Materials and Methods

Literature Search
A literature search was performed using Medline, Ovid, Embase, Google Scholar, Web of Science, and Cochrane databases. All comparative studies published on leukocyte filtration within the CPB circuit, from database inception to early 2007, were sought. The following mesh headings were used: "leukodepletion", "leukodepletion, cardiac surgery", "cardiac", "leukocyte", "leukofiltration", "leukofiltration, cardiac surgery", "comparative study", and "outcome". The "related articles" function was utilized to broaden the search, and all abstracts, studies, and citations were scanned and reviewed. References of the articles acquired were also searched manually. No language restrictions were made. The latest date for this search was January 1, 2007.
Inclusion Criteria
Studies were included for meta-analysis if they met each of the following criteria: (1) were comparative studies, (2) involved open-heart surgery, (3) reported on the effect of systemic leukofiltration (i.e., filter within the arterial or venous line of the cardiopulmonary bypass circuit), (4) reported at least one clinical outcome relating to hemorrhage. Studies assessing additional leukodepleting strategies were included as long as systemic leukofiltration occurred in one arm, alongside the other interventions.
Exclusion Criteria
Studies were excluded from the review if: (1) the trial was carried out on animal models, (2) they published results subsequent to a previously published study (the smallest and the oldest were excluded), (3) systemic filtration had only occurred simultaneous to filtration of the cardioplegic and/or cell-saver line, (4) neither patients nor investigators were blinded to the intervention, (5) a zero cell was displayed for the outcomes of interest for both groups, and (6) inconsistency of data did not allow valid extraction.
Data Extraction and Validation of Studies
Two reviewers (O.W. and S.W.) identified trials for inclusion and independently extracted the following data from each study, according to a prearranged protocol: first author, publication year, institution, study synopsis and design, study population characteristics, number of subjects in each subgroup, and outcome measures. Authors of included trials were contacted when necessary to clarify data and to identify multiple publications. Each reviewer independently assigned each study, if eligible, a JADAD quality score (maximum score ϭ 5) that evaluates the quality of reports of randomized clinical trials. 27 In the case of any discrepancy between reviewers, the decision was taken by consensus.
Outcomes and Definitions
The primary outcomes were defined as (a) postoperative blood loss and (b) total packed red cell (PRC) transfusion requirements. Postoperative blood loss was defined as the amount of blood lost into the chest drains at 24 hours postoperatively, expressed in milliliters. Studies that documented chest drain loss at time points different to this were few, and were excluded to reduce heterogeneity. Studies that documented the number of units of PRCs, but not the number of milliliters, were converted appropriately (one unit of PRCs to 316 ml). 
Statistical Analysis
The group where no leukocyte filtration occurred was regarded as the reference group and that in which a leukode-pleting filter was deployed, the treatment group. Meta-analysis was performed in line with recommendations from the Cochrane Collaboration and the Quality of Reporting of Metaanalyses (QUORUM) guidelines. 28, 29 Because both outcomes were continuous data, the effect measure estimated was weighted mean difference (WMD), reported with 95% confidence intervals (CI). A WMD Ͻ0 favored the leukofiltration group. The point estimate of the WMD was considered statistically significant at the p Ͻ 0.05 levels, if the 95% confidence interval did not include the value zero. Data for the chosen outcomes was entered into Review Manager Version 4.2 (The Cochrane Collaboration, Software Update, Oxford, UK). Pooled estimates, CI, and tests for heterogeneity were calculated and visual evaluation of possible publication bias was performed by the use of funnel plots. 30 In the forest plots of the results, squares indicate point estimates of treatment effect (WMD), and horizontal bars indicate 95% confidence intervals. The diamond represents the summary estimate from the pooled studies with 95% CI. Study Design: 1 ϭ Single blind randomized control trial; 2 ϭ Non-randomized prospective blinded case-control trial; 3 ϭ Double blind randomized control trial. Admission Type: E, elective; U, urgent. Surgical Procedure: a, coronary artery bypass grafting; b, valve replacement surgery; c, congenital heart disease correction; d, coronary artery bypass grafting and valve replacement; e, aortic valve disease surgery. Matching Criteria: 1, age; 2, sex; 3, body surface area; 4, procedure; 5, weight; 6, height; 7, ejection fraction; 8, preoperative full blood count; 9, preoperative other bloods (lipids, troponin, urea, and electrolytes); 10, smoking; 11, hypertension; 12, comorbidities; 13, number of distal anastamoses; 14, internal mammary artery grafts/patient; 15, cardiopulmonary bypass duration; 16, aortic cross clamp time; 17, Parsonnet score; 18, cooling temperature. Exclusion Criteria: A, comorbidity (e.g. renal/cerebral/liver disease, diabetes mellitus or malignancy); B, allergy to certain materials; C, concomitant infection; D, reoperation; E, left ventricular ejection fraction Ͻ30%; F, valvular lesion; G, cardiopulmonary bypass duration of Ͻ60 minutes; H, certain medications e.g. antiplatelets; I, preoperative coagulopathy; J, preoperative platelet level Ͻ75 ϫ 10 9 /L; K, high risk patients (Parsonnet score 10); L, age Ͼ70; M, LVEF Ͼ50%; N, age Ͼ80; O, combined procedures; P, atrial fibrillation; Q, left ventricular aneurysm; R, intraoperative blood transfusion requirements Ͼ6 units; S, age Ͼ75; T, leukocyte count Ͻ5 ϫ 10 9 /L. AXC, aortic cross clamp; C, control group; CI, confidence interval; CPB, cardiopulmonary bypass; Excl., exclusion; Gp., group; HCC, heparin coated circuit; LDALF, leukocyte depleting arterial line filter; LDF, leukocyte depleting filter; LDVLF, leukocyte depleting venous line filter; mls, millilters; n, number; n/a, not apparent; No., number; Ref., reference; WMD, weighted mean difference; Yrs., years. In a fixed-effect model, it is assumed that there is no heterogeneity in treatment effect between studies, whereas in a random-effect model, it is assumed that there is variation between studies, and the calculated weighted mean difference therefore has a more conservative value. 30, 31 In surgical research, and thus in our study, meta-analysis using the randomeffect model is preferable, particularly because patients that are operated on in different centers have varying risk profiles and selection criteria for each surgical technique. 32 Heterogeneity was explored using the 2 statistic, but the I 2 value was calculated to quantify the degree of heterogeneity across trials that could not be attributable to chance alone. I 2 provides a superior measure of heterogeneity between trials as it is independent of the number of trials included in the analysis and is not limited by power. 33, 34 When I 2 Ͼ50, it indicates significant heterogeneity.
Three more strategies were used to quantitatively assess heterogeneity. First, data were reanalyzed by using both randomeffect and fixed-effect models. Second, graphical exploration with funnel plots was used to evaluate publication bias, 35 and re-analysis performed once any outlying studies had been removed from the data. Third, sensitivity analysis was undertaken by using the following subgroups: (1) studies with seven or more matching criteria, i.e., studies with minimal heterogeneity between control and treatment groups; (2) studies with arterial filtration only; (3) higher-quality studies (JADAD score Ն2). These subgroups were identified in the protocol before conducting the review and analysis.
Results
Eligible Studies
Of the 302 publications identified using the above search keywords, 272 were excluded after title and abstract review (Figure 1) . Initially, 30 articles were investigated in detail and their references crosschecked, which yielded a further 38 reports for evaluation. Thus, 68 articles were studied to identify their primary and secondary outcomes. Of these, 14 15,16,21,24,36 -45 fulfilled all the inclusion and exclusion criteria. However, one study had to be withdrawn because inconsistency of data did not allow valid extraction. 36 Therefore, 13 studies published between 1993 and 2005 contributed data for this meta-analysis. These included a combined total of 630 patients, of which 339 (54%) underwent CPB with a control filter and 291 (46%) underwent systemic leukofiltration.
The characteristics of the included studies are shown in Table  1 . Of the 13 studies, 10 had two arms, 15, 16, 24, [37] [38] [39] [40] [41] [42] [43] and 3 had four arms. 21, 44, 45 All but one of the studies 38 were randomized control trials, of which two were double-blinded. 37, 44 shows the number of matching criteria and the JADAD score for the randomized control trials. Eight of the studies matched control and treatment groups for seven or more demographic criteria. 16,21,24,40 -44 The mean JADAD score was 1.34 (range, 1-3), but only three of the studies scored higher than 1, suggesting the overall quality of studies to be relatively poor. [42] [43] [44] 
Results From Overall Meta-analysis
Forest Plots of the meta-analysis of the studies with regard to 24-hour chest tube drainage (ml) and total blood transfused (ml) for control vs. systemic leukofiltration are shown in Figures 2 and 3 . Systemic leukofiltration made no significant impact on chest tube drainage in the first 24 hours, (WMD Ϫ23.9 ml; 95% CI 95.48 to 47.61; p ϭ 0.51) or on the total PRC transfusion requirements of each patient (WMD 7.84 ml; 95% CI Ϫ80.13 to 95.81; p ϭ 0.86). However, while the 6 studies that reported on total PRC transfusion requirements were not significantly heterogeneous ( 2 test 9.6; I 2 47.9%; p ϭ 0.09), the 11 studies included in the chest tube drainage meta-analysis were ( 2 test 108.7; I 2 90.8%; p Ͻ 0.00001), as confirmed by Figure 4 (funnel plot of 11 studies). In an attempt to correct this heterogeneity, the outlying study in Figure 4 was removed, 37 and a subgroup analysis was performed. Importantly, this removed any significant heterogeneity ( 2 test 9.24; I 2 2.6%; p ϭ 0.42). Furthermore, it resulted in a statistically significant fall in chest tube drainage in those patients who underwent systemic leukofiltration when compared to controls (WMD Ϫ15.75ml; 95% CI, Ϫ30.46 to 1.03; p ϭ 0.04) ( Figure  5) . While statistically significant, a 15 ml reduction in chest tube drainage is of negligible clinical significance.
Sensitivity Analysis
The results of all the sensitivity analyses are presented in Table 3 .
Studies With Seven or More Matching Criteria. Sensitivity analysis of this group demonstrated a statistically significant reduction in chest tube drainage in the systemic leukofiltration group (WMD, Ϫ18.13 ml; 95% CI, Ϫ28.26 to Ϫ8.00; p ϭ 0.0005), and removed the previously significant heterogeneity ( 2 test 1.64; I 2 0%; p ϭ 0.9). These results are presented in Figure 6 . However, the clinical significance of an 18 ml reduction in chest tube drainage can only be regarded as minimal. No effect on total blood transfusion requirements was demonstrated.
Studies With Arterial Filtration Only. A sensitivity analysis was performed looking at studies that reported filters placed solely in the arterial line of the CPB circuit, as previous work has demonstrated that arterial line filters may become saturated after approximately 30 minutes, 46 -48 a possible source of bias. This reduced the number of studies that reported on chest tube drainage from 11 to 9, but still resulted in a statistically significant heterogeneity. No significant effect of leukofiltration on chest tube drainage was demonstrated. No sensitivity analysis was required regarding transfusion requirements, as all the studies that reported on this outcome in the original meta-analysis were coincidentally "arterial filtration only".
Higher-Quality Studies (JADAD score >2). Three studies in our meta-analysis scored 2 or higher for their JADAD quality scores. [42] [43] [44] Sensitivity analysis of this group resulted in a significant improvement in the heterogeneity of the data, but found no significant effect of leukofiltration on chest tube drainage in the first 24 hours. Only one of these studies reported on transfusion requirements, 44 and so a sensitivity analysis of that outcome was not possible.
Discussion
The results of this meta-analysis show that there was no clinically significant difference in 24-hour chest tube drainage or total packed red cell transfusion requirements between patients undergoing CPB-assisted cardiac surgery with a standard filter, and those undergoing it with a systemic leukodepleting filter.
Meta-analysis is most effective when randomized studies are analyzed, and in our study, all but one of the included studies were randomized. Furthermore, it has been suggested that in meta-analysis we should place significant weight on explaining the causes for heterogeneity, rather than just focusing on calculating the overall estimates for several outcomes of interest. 49 We have found three key reasons for heterogeneity within our sample: (1) variability in quality of study (as measured by JADAD score 27 ), (2) degree of preoperative matching of study groups, and (3) effect of a particular study where leukofiltration was combined with another intervention. 37 When these factors were corrected, and the data re-analyzed, heterogeneity was eradicated, and in two instances, a clini-cally irrelevant but statistically significant reduction in chest tube drainage was detected.
We have performed the first meta-analysis of studies assessing leukocyte depleting filters and their effect on perioperative hemorrhage, and have used a systematic approach. The importance of our paper is its capacity to guide future work. In recent years, investigators have attempted to enhance the potential of leukofiltration by using various strategies. 21, 22, 50, 51 However, in order to address the uncertainty regarding any potential benefit of leukofiltration, higher-quality, doubleblind randomized controlled trials are required. These trials must have study groups that are both extensively and accurately matched for preoperative variables, particularly pertaining to the primary outcome being assessed. Finally, instead of combining strategies in the hope of maximizing any potential impact of their intervention, they should focus specifically on the single intervention of the addition of a systemic leukodepleting filter into the arterial or venous line of the CPB circuit.
Although a small number of centers use systemic leukodepleting filters routinely, most clinicians remain unconvinced of their efficacy in CPB for a number of reasons. Firstly, while there exists a large number of randomized controlled trials investigating the clinical use of this technology, most are small and have limitations in their methodology. 52 Secondly, while leukodepleting filters do remove leukocytes from a stream of blood, they do not appear to consistently lower leukocyte concentrations within the circulation, or they do it only transiently. 44, 53 Some groups have argued that there is a preferential removal of activated leukocytes, but this remains controversial and largely unproved. 42, 54 Thirdly, and most importantly, although some trials report positive findings in terms of reduction in various markers of organ injury, the great majority fail to report a statistically significant improvement in hard clinical endpoints such as time on ventilator, time in intensive care, time in hospital, and mortality. 52 It is somewhat unsurprising therefore that we have been unable to identify any official guidelines for surgeons or perfusionists supporting the employment of leukodepleting filters in routine practice. Both the Society of Clinical Perfusion Scientists of Great Britain and Ireland and the American Society of Extracorporeal Technology issue guidelines on apparatus but neither recommend leukodepleting filters. 55, 56 Our results certainly suggest that leukofiltration does not confer any benefit in terms of CPBassociated coagulopathy, contrary to what has been suggested elsewhere. 24 
Limitations
This meta-analysis has several limitations that must be taken into account when considering its results. The role and strength of meta-analytic techniques has been a source of extensive debate among epidemiologists. Critics of these techniques argue that the effect of meta-analysis is to "reinforce the inherent systematic biases of the studies, produce spurious statistical stability and discourage further research." 57 However, statistical quantification and pooling of results provides a tool for identifying reasons for variability and inconsistency, and the finding of heterogeneity "sets the stage for further research" on a given topic. 58 One key limitation with this meta-analysis is the small sample size of the included studies. Except for the study by Leal-Noval et al., 43 no study had a treatment group above 40. Only a moderate number of papers proved suitable for inclusion, and those that did were of relatively low quality, as demonstrated by their JADAD scores. Furthermore, we focused on blood loss, and markers of its severity, although in the original studies, this was not the primary endpoint. These key factors make it unlikely that meta-analysis will demonstrate any clinically significant effect.
We focused on the two most frequently cited markers for perioperative hemorrhage. As previously described, in the majority of studies these are surrogate outcomes; the studies having been designed to answer other controversies regarding leukofiltration. There may have therefore been a selection bias in the reporting of these outcomes. Furthermore, the number of potential confounding variables not controlled for in the included studies is relatively high. Only four studies matched their patient groups for preoperative full blood count, one of the triggers many clinicians use when making decisions about transfusing blood products. 15, 21, 40, 43 None of the studies reporting on transfusion requirements report a prospective welldefined protocol for blood transfusion, which means that there is likely to be significant heterogeneity between different units in which criteria lead to the administration of blood products. Furthermore, only two studies accounted for preoperative anticoagulant or antiplatelet agents in their exclusion criteria 37, 42 ; only three studies excluded preoperatively those patients with coagulopathies or thrombocytopenia 37, 43, 44 ; and one study excluded from analysis any patients who received more than 6 units of blood intraoperatively. 37 Finally, we were unable to meta-analyze any data regarding other blood products, such as fresh-frozen plasma and platelets, because their reporting was infrequent and highly heterogeneous. Therefore, there may be patients within the analysis whose hemostasis was impaired before CPB, and in whom the effects of leukocyte filtration are masked by other procoagulants or anticoagulants.
Conclusion
Systemic leukodepletion does not have a clinically significant effect on perioperative blood loss in cardiac surgery. The studies performed in this area thus far are highly heterogeneous, due in part to relatively poor-quality design and inadequate matching of their study groups. Although further good-quality trials on systemic leukofiltration may be appropriate, other strategies to reduce the coagulopathy associated with CPB should be sought and evaluated.
